Table 1.
Laboratory Assessments During Treatment and Follow-up.
| Laboratory Assessments | February 2019 Baseline | May 2019 C2 | June 2019 C3 | July 2019 C4 | August 2019 C5 | October 2019 EOT | January 2020 Follow-up | June 2020 Follow-up | October 2020 Follow-up | March 2021 Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| Total urine protein (g/24 h) | 9.6 | 6.8 | 4.1 | 3.8 | 2.6 | 3.5 | 2.1 | 0.718 | ||
| Serum Cr (mg/dL) | 1.0 | 1.22 | 1.03 | 0.86 | 0.88 | 0.97 | 0.96 | 1.13 | 1.0 | 1.13 |
| eGFR (mL/min/1.73 m2) | 78.52 | 62.42 | 75.88 | 93.44 | 91 | 81.32 | 82.3 | 67.9 | 78.29 | 67.8 |
| κLC (mg/L) (3.3–19.4) | 38.2 | 12.0 | 24.0 | 21.2 | 19.3 | 17.61 | 27.5 | 34.6 | 29.3 | 19.8 |
| λLC (mg/L) (5.71–26.3) | 56.1 | 8.09 | 15.8 | 11.4 | 12.6 | 10.3 | 16.4 | 18.9 | 19.0 | 16.5 |
| κ/λ (0.26–1.65) | 0.68 | 1.48 | 1.52 | 1.86 | 1.53 | 1.71 | 1.68 | 1.83 | 1.54 | 1.20 |
| dFLC | 18.1 | N/E | N/E | N/E | N/E | N/E | N/E | N/E | N/E | |
| Serum IFx | IgGλ | IgGλ | IgGλ | (–) | (–) | (–) | (–) | (–) | (–) | (–) |
| Urine IFx | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) | (–) |
| NGF clone detection—MRD | + | (–) | ||||||||
| NT-proBNP (pg/mL) | 2192 | 1566 | 2183 | 1664 | 2652 | 1488 | 1976 | 1722 | 1320 |
Cr = creatinine; dFLC = difference between involved and uninvolved free light chain; eGFR = estimated glomerular filtration rate; EOT = end of treatment; IFx = immunofixation; MRD = minimal residual disease; N/E = non evaluable; NGF = next generation flow for the assessment of minimal residual disease; NT-proBNP = N-terminal pro-B-type natriuretic peptide; κLC = kappa serum free light chain; λLC = lambda free light chain.